36.22 USD
-0.19 (-0.52%)
36.22 USD
0 (0%)
We assign a fundamental rating of 8 out of 10 to HRMY. HRMY was compared to 190 industry peers in the Pharmaceuticals industry. HRMY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: HRMY is growing strongly while it also seems undervalued. This makes HRMY very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
- HRMY had positive earnings in the past year.
- HRMY had a positive operating cash flow in the past year.
- HRMY had positive earnings in 4 of the past 5 years.
- HRMY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 15.37%, HRMY belongs to the best of the industry, outperforming 95.26% of the companies in the same industry.
- HRMY has a Return On Equity of 22.23%. This is amongst the best in the industry. HRMY outperforms 92.63% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 17.20%, HRMY belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
- HRMY had an Average Return On Invested Capital over the past 3 years of 18.27%. This is significantly above the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROIC | 17.2% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
- The Profit Margin of HRMY (22.48%) is better than 91.58% of its industry peers.
- In the last couple of years the Profit Margin of HRMY has grown nicely.
- HRMY has a better Operating Margin (27.32%) than 93.16% of its industry peers.
- HRMY's Operating Margin has declined in the last couple of years.
- The Gross Margin of HRMY (77.70%) is better than 83.16% of its industry peers.
- HRMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
- HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, HRMY has more shares outstanding
- The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
- HRMY has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.44 indicates that HRMY is not in any danger for bankruptcy at the moment.
- HRMY has a Altman-Z score of 5.44. This is in the better half of the industry: HRMY outperforms 74.74% of its industry peers.
- HRMY has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
- The Debt to FCF ratio of HRMY (0.57) is better than 96.84% of its industry peers.
- A Debt/Equity ratio of 0.18 indicates that HRMY is not too dependend on debt financing.
- HRMY has a Debt to Equity ratio (0.18) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Altman-Z | 5.44 |
ROIC/WACC1.81
WACC9.48%
2.3 Liquidity
- A Current Ratio of 3.75 indicates that HRMY has no problem at all paying its short term obligations.
- HRMY has a Current ratio (3.75) which is in line with its industry peers.
- A Quick Ratio of 3.72 indicates that HRMY has no problem at all paying its short term obligations.
- HRMY's Quick ratio of 3.72 is in line compared to the rest of the industry. HRMY outperforms 58.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
- HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.71%, which is quite impressive.
- Measured over the past years, HRMY shows a very strong growth in Earnings Per Share. The EPS has been growing by 44.61% on average per year.
- The Revenue has grown by 21.13% in the past year. This is a very strong growth!
- The Revenue has been growing by 160.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
3.2 Future
- Based on estimates for the next years, HRMY will show a very strong growth in Earnings Per Share. The EPS will grow by 35.10% on average per year.
- The Revenue is expected to grow by 14.79% on average over the next years. This is quite good.
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.79%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 11.39, the valuation of HRMY can be described as reasonable.
- Based on the Price/Earnings ratio, HRMY is valued cheaper than 89.47% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.47, HRMY is valued rather cheaply.
- A Price/Forward Earnings ratio of 8.57 indicates a reasonable valuation of HRMY.
- 90.53% of the companies in the same industry are more expensive than HRMY, based on the Price/Forward Earnings ratio.
- HRMY is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.39 | ||
| Fwd PE | 8.57 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaply inside the industry as 94.74% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, HRMY is valued cheaper than 96.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.03 | ||
| EV/EBITDA | 6.28 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of HRMY may justify a higher PE ratio.
- A more expensive valuation may be justified as HRMY's earnings are expected to grow with 25.00% in the coming years.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y29.75%
EPS Next 3Y25%
5. Dividend
5.1 Amount
- HRMY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
36.22
-0.19 (-0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-23 2026-02-23/amc
Inst Owners85.16%
Inst Owner Change2.11%
Ins Owners1.63%
Ins Owner Change-61.8%
Market Cap2.09B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target47.11 (30.07%)
Short Float %8.89%
Short Ratio5.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)0%
PT rev (3m)3.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.87%
EPS NY rev (1m)0%
EPS NY rev (3m)2.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.39 | ||
| Fwd PE | 8.57 | ||
| P/S | 2.53 | ||
| P/FCF | 7.03 | ||
| P/OCF | 7.01 | ||
| P/B | 2.5 | ||
| P/tB | 2.82 | ||
| EV/EBITDA | 6.28 |
EPS(TTM)3.18
EY8.78%
EPS(NY)4.23
Fwd EY11.67%
FCF(TTM)5.15
FCFY14.23%
OCF(TTM)5.17
OCFY14.27%
SpS14.34
BVpS14.5
TBVpS12.84
PEG (NY)0.38
PEG (5Y)N/A
Graham Number32.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROCE | 22.91% | ||
| ROIC | 17.2% | ||
| ROICexc | 54.26% | ||
| ROICexgc | 78.12% | ||
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% | ||
| FCFM | 35.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 3% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 14.73 | ||
| Cash Conversion | 119.28% | ||
| Profit Quality | 159.9% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | 5.44 |
F-Score6
WACC9.48%
ROIC/WACC1.81
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y29.83%
EPS Next 2Y29.75%
EPS Next 3Y25%
EPS Next 5Y35.1%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year20.8%
Revenue Next 2Y18.45%
Revenue Next 3Y16.54%
Revenue Next 5Y14.79%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year37.1%
EBIT Next 3Y27.64%
EBIT Next 5Y23.54%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
What is the valuation status of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What are the PE and PB ratios of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 11.39 and the Price/Book (PB) ratio is 2.5.
What is the earnings growth outlook for HARMONY BIOSCIENCES HOLDINGS?
The Earnings per Share (EPS) of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 29.83% in the next year.